Pazopanib

Catalog No.S3012 Synonyms: GW786034

Pazopanib Chemical Structure

Molecular Weight(MW): 437.52

Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • (a,b) Effect of Pazopanib on vascular network integrity. VMOs were exposed to drug from day 4 to 6. Data are normalized to day of first drug exposure and are shown as percentage of control. Error bars show mean ± s.d (n = 3) (p < 0.05 vs control).

    Sci Rep, 2016, 6:31589. Pazopanib purchased from Selleck.

    J Virol 2011 85(5), 2296-303. Pazopanib purchased from Selleck.

  • Three RCC cell lines treated with different concentrations of TKI and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib purchased from Selleck.

    (B) The effects of AZD2014, BEZ235, lapatinib, LEE011, pazopanib on PI3K/AKT signaling in sarcoma PDC line were determined by immunoblotting analysis. Cells were treated with 1 μM of the indicated drugs for 72 h.

    Transl Oncol, 2016, 9(3):197-202. Pazopanib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] PPazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human EoL-1-cell cell MVfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn3yTY5pcWKrdHnvckBw\iCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIHnjOVA:Oi56OXWtNFUh|ryP MkSxV2FPT0WU
human AN3-CA cell NITWeGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlXzTY5pcWKrdHnvckBw\iCqdX3hckBCVjNvQ1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE4xPSCwTR?= MYrTRW5ITVJ?
human CGTH-W-1 cell M4[1Wmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjtUHpuUW6qaXLpeIlwdiCxZjDoeY1idiCFR2TIMXcuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRyLkCxJI5O MnnkV2FPT0WU
human GDM-1 cell NY\iXoZDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUHJcohq[mm2aX;uJI9nKGi3bXHuJGdFVS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUCzMlk6KG6P MmjDV2FPT0WU
human A204 cell MojFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NG\6fGhKdmirYnn0bY9vKG:oIHj1cYFvKEF{MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNFkvODZibl2= M{TGVHNCVkeHUh?=
human G-402 cell M1vhZ2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoLITY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWzNU45PCCwTR?= MYjTRW5ITVJ?
human MFE-296 cell NHfJblZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnzsTY5pcWKrdHnvckBw\iCqdX3hckBOTkVvMkm2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42QTB{MjFOwG0> NHjyU|ZUSU6JRWK=
human NOS-1 cell MoHTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJIlkPTB;MD62OVk5PyEQvF2= NX\0NYxxW0GQR1XS
human KG-1 cell M2rlW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3W4VWlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|E4PTVizszN MorNV2FPT0WU
human HT55 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1PFUmlvcGmkaYTpc44hd2ZiaIXtZY4hUFR3NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg4QDFizszN MXjTRW5ITVJ?
human MG-63 cell M2XKNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{nCWGlvcGmkaYTpc44hd2ZiaIXtZY4hVUdvNkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlAxOTR4IN88US=> M{nlUnNCVkeHUh?=
human CCF-STTG1 cell MkfrS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHnDWY1KdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;MT6wOFk5OSEQvF2= MVrTRW5ITVJ?
human RT-112 cell NIX0PXpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfoUYNuUW6qaXLpeIlwdiCxZjDoeY1idiCUVD2xNVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjFyM{e2JO69VQ>? NVvPeYpmW0GQR1XS
human MC-IXC cell NF7pcIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Ml72TY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlEyPTF{IN88US=> M{X5fXNCVkeHUh?=
human HUTU-80 cell NGjVVJZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJGhWXFVvOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlI5OTB|IN88US=> Mm\hV2FPT0WU
human MV-4-11 cell MmnnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NULkXo1FUW6qaXLpeIlwdiCxZjDoeY1idiCPVj20MVEyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|NEWwNUDPxE1? MmqzV2FPT0WU
human LCLC-103H cell MoD2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkWzTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigQ>? M4GzZnNCVkeHUh?=
human G-401 cell NIXhcY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NF7yS5VKdmirYnn0bY9vKG:oIHj1cYFvKEdvNECxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU41PjR{MTFOwG0> MoS4V2FPT0WU
human A704 cell MmPNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV70WJhvUW6qaXLpeIlwdiCxZjDoeY1idiCDN{C0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43ODN{MzFOwG0> NW[xe4JKW0GQR1XS
human ESS-1 cell NH;kSXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYDJcohq[mm2aX;uJI9nKGi3bXHuJGVUWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT62NFM6PiEQvF2= M1LtSnNCVkeHUh?=
human HLE cell MoHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MoixTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLk[zPFA1KM7:TR?= MWPTRW5ITVJ?
human NY cell MoHHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWnJcohq[mm2aX;uJI9nKGi3bXHuJG5[KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS56NEiyNUDPxE1? NFTxSXlUSU6JRWK=
human A427 cell NXj1XGxIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV7GTWRIUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU46QDB5NTFOwG0> M3G5UXNCVkeHUh?=
human SK-N-DZ cell NFX0fYpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDGPZRKdmirYnn0bY9vKG:oIHj1cYFvKFONLV6tSHoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjB{M{ixJO69VQ>? MVnTRW5ITVJ?
human J82 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NFHQUHBKdmirYnn0bY9vKG:oIHj1cYFvKEp6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFYxQDhizszN MnnWV2FPT0WU
human GI-1 cell M4ezSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXjJcohq[mm2aX;uJI9nKGi3bXHuJGdKNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1{LkKyPVUyKM7:TR?= MVHTRW5ITVJ?
human NCI-H716 cell M124Omdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYPGR3hiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFcyPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwM{G2N|Mh|ryP NIfreJFUSU6JRWK=
human SF126 cell NUDr[2FLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2rqb2lvcGmkaYTpc44hd2ZiaIXtZY4hW0ZzMk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlQ4PDV7IN88US=> NFnqc41USU6JRWK=
human H4 cell MkT0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkDDTY5pcWKrdHnvckBw\iCqdX3hckBJPCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwNUGyOlIh|ryP M2rmTXNCVkeHUh?=
human LB831-BLC cell NH:yc5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3zkdGlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ6M{GtRmxEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53NEW2OkDPxE1? M1G4XXNCVkeHUh?=
human HCC1395 cell NYe2b45ZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWjKSpJuUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OxN|k2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi53OEG1OkDPxE1? MoPnV2FPT0WU
human LK-2 cell M1;JcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3XPRmlvcGmkaYTpc44hd2ZiaIXtZY4hVEtvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOlQ2PjlizszN M3S4NHNCVkeHUh?=
human G-361 cell MoK0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{XSdWlvcGmkaYTpc44hd2ZiaIXtZY4hTy1|NkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlA1ODh{IN88US=> NX;1d4drW0GQR1XS
human NCI-H2342 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkO0NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NiCLQ{WwQVMvOTN|MU[g{txO M1LMN3NCVkeHUh?=
human SK-LU-1 cell  MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlWwTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4yQDd4NzFOwG0> M2LNXnNCVkeHUh?=
human IGROV-1 cell  NE[0PW9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWrlR|ZMUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy5{NEexN{DPxE1? MkfLV2FPT0WU
human EB2 cell MnXiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NH62OJpKdmirYnn0bY9vKG:oIHj1cYFvKEWEMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNlgyPjhizszN NVfPUYdTW0GQR1XS
human CAL-54 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWH5NZdNUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ6M{[3JO69VQ>? MnPvV2FPT0WU
human LB1047-RCC cell MkHGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlPXTY5pcWKrdHnvckBw\iCqdX3hckBQS1WELV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlM{OTN4ODFOwG0> NE\IXWNUSU6JRWK=
Daudi cell NHX2e3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjaTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oy53M{G2OEDPxE1? M2Hoe3NCVkeHUh?=
human Daudi cell NVfkPWF1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mm[yTY5pcWKrdHnvckBw\iCqdX3hckBF[XWmaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlYzOTlizszN MnL1V2FPT0WU
human A172 cell MnXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXXJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1|LkezO|kh|ryP NWr3XWNIW0GQR1XS
human KGN cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4m1TGlvcGmkaYTpc44hd2ZiaIXtZY4hU0eQIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND6wOlcxQSEQvF2= M1r6W3NCVkeHUh?=
human SNG-M cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M17CRmlvcGmkaYTpc44hd2ZiaIXtZY4hW06JLV2gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlA5PjZ7IN88US=> NYX4R3BUW0GQR1XS
human SW1710 cell NHzGWXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYLXeox5UW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjR5M{G4JO69VQ>? NFXZUphUSU6JRWK=
human HT29 cells Mn71VJJwdGmoZYLheIlwdiCjc4PhfS=> NF[1T4VCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUNlkh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= NETpOGsyQDZ{MEO4Ni=>
human A375P cells M1O5d3Bzd2yrZnXyZZRqd25iYYPzZZk> M17CdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUO3OXAh[2WubIOgbY4he2W{dX2gZ49vfGGrbnnu[{Bu\WSrdX2= M33mRlE5PjJyM{iy
human HN5 cells NGPRRo1Rem:uaX\ldoF1cW:wIHHzd4F6 NHLpV3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjOOUBk\WyuczDpckB{\XK3bTDjc451[WmwaX7nJI1m\Gm3bR?= M3jGdlE5PjJyM{iy
HUVEC NHzpfWVHfW6ldHnvckBie3OjeR?= MlPGNUDPxE1? M{XWRVYhcA>? NES1T2RCdnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1ZoUh\m:{bXH0bY9vKGG2IECuNUB2VSCjZoTldkA3KGi{czDifUBO[XS{aXflcEBie3OjeR?= NVTUdm9JOjRyM{[wOFI>
human Daoy cell M{TNe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUjJcohq[mm2aX;uJI9nKGi3bXHuJGRid3liY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12Lke3PVQ6KM7:TR?= MYrTRW5ITVJ?
human DMS-273 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MojzTY5pcWKrdHnvckBw\iCqdX3hckBFVVNvMkezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46PjJyMjFOwG0> M3vDU3NCVkeHUh?=
human KU812 cell M{\m[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXDdWJKdmirYnn0bY9vKG:oIHj1cYFvKEuXOEGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PzhzMjFOwG0> NV\MZ5ZPW0GQR1XS
human NCI-H727 cell M2S5fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnXMTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEeyO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPDB7MEGg{txO M3XVS3NCVkeHUh?=
human P30-OHK cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYjnTIJYUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52Nkm0JO69VQ>? NYjtc|E4W0GQR1XS
human MIA-PaCa-2 cell NY\JO4tyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mk[wTY5pcWKrdHnvckBw\iCqdX3hckBOUUFvUHHDZU0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS54MES2OkDPxE1? Mm\ZV2FPT0WU
human TT cell NXrtcG0zT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1PjVmlvcGmkaYTpc44hd2ZiaIXtZY4hXFRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lk[2NlQh|ryP NVXDXGQ3W0GQR1XS
human DK-MG cell NVOw[5d2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEjofW5KdmirYnn0bY9vKG:oIHj1cYFvKESNLV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44OjB{ODFOoI0> NXXLenVmW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Animal Research:

[2]

+ Expand
  • Animal Models: Immunodeficient mice bearing SYO-1 cells
  • Formulation: --
  • Dosages: 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 87 mg/mL warmed (198.84 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 437.52
Formula

C21H23N7O2S

CAS No. 444731-52-6
Storage powder
in solvent
Synonyms GW786034

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02300545 Recruiting Sarcoma, Soft Tissue|Soft Tissue Sarcoma Washington University School of Medicine April 8, 2015 Phase 2
NCT00674024 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 7, 2008 Phase 1
NCT01716416 Recruiting Squamous Cell Carcinoma of the Head and Neck Washington University School of Medicine May 31, 2013 Phase 1
NCT01462630 Recruiting Adult Angiosarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma Fox Chase Cancer Center|National Cancer Institute (NCI) November 3, 2011 Phase 2
NCT01468922 Completed Sarcoma|Stomach Neoplasms|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 24, 2011 Phase 1
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

Related VEGFR Products

Tags: buy Pazopanib | Pazopanib supplier | purchase Pazopanib | Pazopanib cost | Pazopanib manufacturer | order Pazopanib | Pazopanib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID